FDA delivers split decision on GSK’s blood cancer drug Blenrep, approving its use in some cases The drug was pulled from the market in 2022 after concerns about efficacy

https://www.statnews.com/2025/10/23/fda-approves-blenrep-gsk-drug-multiple-myeloma/